242535 Using the PCMH Model to Manage Antipsychotic Medications in Underserved Populations

Monday, October 31, 2011: 10:50 AM

Jane N. Bolin, PhD, JD, RN , Health Policy & Management, Texas A&M HSC School of Rural Public Health, College Station, TX
RESEARCH OBJECTIVE: Increasingly state mental health agencies are unable to treat the rising numbers of patients seeking mental health services with many patients experiencing waiting times of several months for treatment. Especially vulnerable are rural, minority and uninsured populations in need of mental health treatment for psychotic conditions. It is well documented that antipsychotic medications may expose patients to the risk of adverse outcomes if not managed correctly. Adverse outcomes include diabetes, hypertension and death. The objective of this study is to evaluate the implementation of antipsychotic medication protocol (AMP) in a large, 21 clinic FQHC Patient Centered Medical Home serving a large population of minority patients in a large southern state with multi-specialty services under the care of mental health specialists employed by the PCMH. STUDY DESIGN: This 3-year study examines the implementation of antipsychotic medication monitoring protocol in a population of rural, underserved and minority patients receiving treatment for psychotic disorders, including schizophrenia. Provider and staff compliance in meeting recommended monitoring of antipsychotic medication protocol are examined at 12 months and two years. PRINCIPAL FINDINGS: Individuals receiving antipsychotic medications are especially at risk for adverse outcomes if not managed correctly. The PCMH model provides ability to closely monitor patients prescribed antipsychotic medications. Methods and standards to efficiently manage and monitor antipsychotic medication is necessary to document the mental health needs of all populations. This study will help enhance and refine best-practice standards for antipsychotic medication management within a PCMH serving patients from children to adults.

Learning Areas:
Chronic disease management and prevention
Clinical medicine applied in public health
Diversity and culture

Learning Objectives:
Evaluate and describe the implementation of best practice standards, and patient-level outcomes related to antipsychotic medication protocol monitoring and management in rural and underserved populations.

Keywords: Organizational Change, Mental Illness

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: Dr. Jane Nelson Bolin Co-PI for the TAMHSC CST*R Institute, in her current position as Director of the Southwest Rural Health Research Center and as Co-PI on the NIH funded CTSA P-20 Strategic Planning grant planning the establishment of the Clinical Translational Science and Research Institute (CST*R). Dr. Bolin has also served as PI or Co-PI on several related diabetes or chronic disease evaluation studies, as PI on a cost-effectiveness analysis grant for the State of Missouri. and has served as PI or Co-PI on numerous other grants involving chronic disease management. Dr. Bolin received her BSN degree from the Oregon Health Sciences University (1978) and, after nursing school, worked for 3 years in an ICU-CCU in Eugene, Oregon. Dr. Bolin graduated from the University of Oregon law school in 1982 and practiced law for 15 years in health-care related law. While Dr. Bolinís primary academic and teaching focus is in the area of health law, ethics, and health regulations, Dr. Bolin also has applied academic and research experience in minority health disparities and the problem of chronic diseases as they affect rural and minority (underserved) populations. Dr. Bolin is currently Co-PI on an NIH-NCMHD P-20 grant entitled Employing Diabetes Self-Management Models to Reduce Health Disparities in Texas, a five-year NIH grant funded in October 2007.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.